ATE279922T1 - Behandlung von zns-wirkungen des hiv mit vx-478, allein oder kombiniert mit azt oder 3tc - Google Patents

Behandlung von zns-wirkungen des hiv mit vx-478, allein oder kombiniert mit azt oder 3tc

Info

Publication number
ATE279922T1
ATE279922T1 AT96942917T AT96942917T ATE279922T1 AT E279922 T1 ATE279922 T1 AT E279922T1 AT 96942917 T AT96942917 T AT 96942917T AT 96942917 T AT96942917 T AT 96942917T AT E279922 T1 ATE279922 T1 AT E279922T1
Authority
AT
Austria
Prior art keywords
azt
hiv
alone
treatment
combined
Prior art date
Application number
AT96942917T
Other languages
English (en)
Inventor
Pravin Ramsewak Chaturvedi
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Application granted granted Critical
Publication of ATE279922T1 publication Critical patent/ATE279922T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT96942917T 1995-12-05 1996-12-05 Behandlung von zns-wirkungen des hiv mit vx-478, allein oder kombiniert mit azt oder 3tc ATE279922T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/567,199 US5646180A (en) 1995-12-05 1995-12-05 Treatment of the CNS effects of HIV
PCT/US1996/019447 WO1997020554A1 (en) 1995-12-05 1996-12-05 Treatment of the cns effects of hiv with vx-478, alone or in combination with azt or 3tc

Publications (1)

Publication Number Publication Date
ATE279922T1 true ATE279922T1 (de) 2004-11-15

Family

ID=24266147

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96942917T ATE279922T1 (de) 1995-12-05 1996-12-05 Behandlung von zns-wirkungen des hiv mit vx-478, allein oder kombiniert mit azt oder 3tc

Country Status (23)

Country Link
US (1) US5646180A (de)
EP (1) EP0866696B1 (de)
JP (1) JP2000501713A (de)
KR (1) KR19990071750A (de)
CN (1) CN1203530A (de)
AP (1) AP864A (de)
AT (1) ATE279922T1 (de)
AU (1) AU722850B2 (de)
BR (1) BR9611861A (de)
CA (1) CA2238471A1 (de)
CZ (1) CZ291994B6 (de)
DE (1) DE69633680T2 (de)
ES (1) ES2231828T3 (de)
HU (1) HUP9903673A3 (de)
NO (1) NO317837B1 (de)
NZ (1) NZ324603A (de)
OA (1) OA10691A (de)
PL (1) PL187747B1 (de)
PT (1) PT866696E (de)
RU (1) RU2203658C2 (de)
UA (1) UA61902C2 (de)
WO (1) WO1997020554A1 (de)
ZA (1) ZA9610139B (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107499A (en) * 1988-02-26 2000-08-22 Neuromedica, Inc. Dopamine analog amide
US5942253A (en) 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
US6576636B2 (en) 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US6486136B1 (en) * 1996-06-25 2002-11-26 Smithkline Beecham Corporation Combinations comprising VX478, zidovudine and/or 1592U89 for use in the treatment of HIV
AP9801419A0 (en) * 1996-06-25 1998-12-31 Glaxo Group Ltd Combination comprising VX478, zidovudine, FTC and or 3
ZA9710071B (en) * 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.
US6232333B1 (en) 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
NZ500868A (en) * 1997-05-17 2001-08-31 Glaxo Group Ltd Antiviral combinations comprising 1592U89 and HIV protease inhibitors
WO1998057648A1 (en) * 1997-06-16 1998-12-23 Vertex Pharmaceuticals Incorporated Methods of increasing the bioavailability of stable crystal polymorphs of a compound
US6576231B2 (en) * 1997-09-12 2003-06-10 Schering Ag Methods for treating HIV-Infected Patients by the Administration of GM-CSF and a protease inhibitor
US6197764B1 (en) 1997-11-26 2001-03-06 Protarga, Inc. Clozapine compositions and uses thereof
US5977174A (en) * 1997-11-26 1999-11-02 Neuromedica, Inc. Cholinergic compositions and uses thereof
US5955459A (en) * 1997-11-26 1999-09-21 Neuromedica, Inc. Fatty acid-antipsychotic compositions and uses thereof
US6153653A (en) * 1997-11-26 2000-11-28 Protarga, Inc. Choline compositions and uses thereof
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
US6309632B1 (en) * 1998-04-28 2001-10-30 Immunex Corporation Methods for treating HIV-infected patients by administering GM-CSF
US6875773B1 (en) * 1998-05-29 2005-04-05 Ben M. Dunn Combination therapy for treatment of FIV infection
US20090197827A1 (en) * 1998-05-29 2009-08-06 Dunn Ben M Combination Therapy for Treatment of FIV Infection
US7235583B1 (en) * 1999-03-09 2007-06-26 Luitpold Pharmaceuticals, Inc., Fatty acid-anticancer conjugates and uses thereof
US6417189B1 (en) 1999-11-12 2002-07-09 Gpi Nil Holdings, Inc. AZA compounds, pharmaceutical compositions and methods of use
DK1328213T3 (da) * 2000-10-16 2005-11-28 Conor Medsystems Inc Ekspanderbar medicinsk indretning til afgivelse af et nyttigt middel
ES2387562T3 (es) * 2001-03-23 2012-09-26 Luitpold Pharmaceuticals, Inc. Conjugados alcohol graso-medicamento
EP1427407A4 (de) 2001-03-23 2005-05-11 Luitpold Pharm Inc Fettamin-arzneimittel-konjugate
EP2266590A3 (de) 2002-02-22 2011-04-20 Shire LLC Wirkstoff-Abgabesystem und Verfahren zum Schutz und zur Verabreichung von Wirkstoffen
US7871991B2 (en) 2004-07-27 2011-01-18 Gilead Sciences, Inc. Phosphonate analogs of HIV inhibitor compounds
AU2006206399B2 (en) * 2005-01-20 2012-04-05 University Of Rochester Compositions and methods relating to mitochondrial hyperpolarization in neurological disease
CA2634932A1 (en) * 2005-12-23 2007-07-05 University Of Rochester Treatment of neuroaids using inhibitors of glycogen synthase kinase (gsk)-3
US8642642B2 (en) * 2006-04-19 2014-02-04 Abbott Laboratories Heterocyclic arylsulphones suitable for treating disorders that respond to modulation of the serotonin 5HT6 receptor
CN102272134B (zh) 2008-12-09 2013-10-16 吉里德科学公司 Toll样受体调节剂
US20110223131A1 (en) 2010-02-24 2011-09-15 Gilead Sciences, Inc. Antiviral compounds
EP3110381B1 (de) 2014-02-28 2020-07-15 Attends Healthcare Products, Inc. Saugfähiger artikel mit mehrschichtigem gefalteten saugfähigen kern
WO2016001907A1 (en) 2014-07-02 2016-01-07 Prendergast Patrick T Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
AU2015287773B2 (en) 2014-07-11 2018-03-29 Gilead Sciences, Inc. Modulators of toll-like receptors for the treatment of HIV
CA2997955A1 (en) 2015-09-15 2017-03-23 Gilead Sciences, Inc. Modulators of toll-like receptors for the treatment of hiv
MX2020012801A (es) 2018-05-28 2021-03-25 Attends Healthcare Products Inc Laminado con capa de sequedad para articulos absorbentes.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
AU5748194A (en) * 1992-12-11 1994-07-04 Vertex Pharmaceuticals Incorporated Mannitol derivatives and their use as inhibitors of aspartyl protease

Also Published As

Publication number Publication date
CA2238471A1 (en) 1997-06-12
AU1148697A (en) 1997-06-27
BR9611861A (pt) 1999-05-18
NO982556D0 (no) 1998-06-04
NO317837B1 (no) 2004-12-20
NZ324603A (en) 2000-08-25
NO982556L (no) 1998-06-04
HUP9903673A3 (en) 2000-08-28
ES2231828T3 (es) 2005-05-16
AP864A (en) 2000-08-11
KR19990071750A (ko) 1999-09-27
US5646180A (en) 1997-07-08
EP0866696A1 (de) 1998-09-30
JP2000501713A (ja) 2000-02-15
CZ170898A3 (cs) 1998-09-16
HUP9903673A2 (hu) 2000-03-28
OA10691A (en) 2001-05-04
WO1997020554A1 (en) 1997-06-12
CZ291994B6 (cs) 2003-07-16
PL187747B1 (pl) 2004-09-30
DE69633680T2 (de) 2006-02-23
DE69633680D1 (de) 2004-11-25
AU722850B2 (en) 2000-08-10
AP9801340A0 (en) 1998-09-30
PT866696E (pt) 2005-03-31
UA61902C2 (en) 2003-12-15
EP0866696B1 (de) 2004-10-20
ZA9610139B (en) 1997-06-17
PL327061A1 (en) 1998-11-23
RU2203658C2 (ru) 2003-05-10
CN1203530A (zh) 1998-12-30

Similar Documents

Publication Publication Date Title
ATE279922T1 (de) Behandlung von zns-wirkungen des hiv mit vx-478, allein oder kombiniert mit azt oder 3tc
DE122009000012I1 (de) Substituierte pyrazolyl-benzolsulfonamide zur behandlung von entzundungen.
ATE110556T1 (de) Verbesserungen bei der behandlung von zähnen.
DE69421100D1 (de) Aufbereitung von schweren endprodukten des fischer-tropsch-verfahrens
DK0811110T3 (da) Oliekildebehandling
DE69430903T2 (de) Behandlung von periodontitis mit misoprostol
DE3576328D1 (de) Behandlung feuerfester gegenstaende.
DE68907423T2 (de) Behandlung der Akne.
NO911431D0 (no) Behandling av stoffer.
ATE257708T1 (de) Kombinationen enthaltend vx478, zidovudin und 3tc zur behandlung von hiv
DE69405711D1 (de) Behandlung von rueckstandsoel
DE69012627D1 (de) Behandlung von Aluminiumlegierungen.
DE69622461D1 (de) Oberflächenbehandlungszusammensetzung
NO881629L (no) Anvendelse av antigene stoffer ved behandling av lidelseri mage-tarm-kanalen.
DE68923219D1 (de) Behandlung von Abfällen.
DE3871010D1 (de) Behandlung von unfruchtbarkeit.
DE69619051D1 (de) Behandlung von Füllstoffen mit Oxasilacycloalkanen
DE68908344D1 (de) Oberflaechenbehandlung von metallen.
DE69302799D1 (de) Zusammensetzung für die Behandlung von Kesselwasser
DE69101847T2 (de) Zubereitung für die Verhütung oder die Behandlung von Hypertriglyceridämie.
FI951655A0 (fi) H.pylori -infektioiden hoito
BR9610382A (pt) Composição de tratamento do cableo
DE69601154D1 (de) Zubereitungen für die Behandlung von Hepatitis C
DE69522685T2 (de) Behandlung von blut-plasma
DE68908413D1 (de) Behandlung von metallbrammen.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0866696

Country of ref document: EP

REN Ceased due to non-payment of the annual fee